Cardiff Oncology Inc (NASDAQ: CRDF) stock closed at $4.48 on 3/12/24 after a major increase of 10.9%. NORMAL trading volume accompanied the advance. The stock has risen 28.4% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
CRDF is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Cardiff Oncology has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Cardiff Oncology has a very low Appreciation Score of 3 but a good Power Rating of 76, producing the Negative Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment